Stock Research for UTHR


Featured Broker: Ally Invest

Get the due diligence for another stock.


UTHR Stock Chart & Research Data

The UTHR chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the UTHR chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


UTHR Due diligence Resources & Stock Charts

The UTHR stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View UTHR Detailed Price Forecast - CNN Money CNN View UTHR Detailed Summary - Google Finance
Yahoo View UTHR Detailed Summary - Yahoo! Finance Zacks View UTHR Stock Research & Analysis -

Stock Analysis

TradeIdeas View UTHR Trends & Analysis - Trade-Ideas Barrons View UTHR Major Holders - Barrons
NASDAQ View UTHR Call Transcripts - NASDAQ Seeking View UTHR Breaking News & Analysis - Seeking Alpha
Spotlight View UTHR Annual Report - OTC Report View UTHR OTC Short Report -
TradeKing View UTHR Fundamentals - TradeKing Charts View UTHR SEC Filings - Bar Chart
WSJ View Historical Prices for UTHR - The WSJ Morningstar View Performance/Total Return for UTHR - Morningstar
MarketWatch View the Analyst Estimates for UTHR - MarketWatch CNBC View the Earnings History for UTHR - CNBC
StockMarketWatch View the UTHR Earnings - StockMarketWatch MacroAxis View UTHR Buy or Sell Recommendations - MacroAxis
Bullish View the UTHR Bullish Patterns - American Bulls Short Pains View UTHR Short Pain Metrics -

Social Media Mentions

StockTwits View UTHR Stock Mentions - StockTwits PennyStocks View UTHR Stock Mentions - PennyStockTweets
Twitter View UTHR Stock Mentions - Twitter Invest Hub View UTHR Investment Forum News - Investor Hub
Yahoo View UTHR Stock Mentions - Yahoo! Message Board Seeking Alpha View UTHR Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for UTHR - Insider Cow View Insider Transactions for UTHR - Insider Cow
CNBC View UTHR Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for UTHR - OTC Markets
Yahoo View Insider Transactions for UTHR - Yahoo! Finance NASDAQ View Institutional Holdings for UTHR - NASDAQ

Stock Charts

FinViz View UTHR Stock Insight & Charts - StockCharts View UTHR Investment Charts -
BarChart View UTHR Stock Overview & Charts - BarChart Trading View View UTHR User Generated Charts - Trading View

Latest Financial News for UTHR

Why Vertex Is Expected to Report Robust EPS Growth in 2018
Posted on Thursday August 16, 2018

How Is Vertex Pharmaceuticals Positioned in August? In its Q2 2018 earnings conference call, Vertex Pharmaceuticals (VRTX) reiterated its projection for non-GAAP combined selling, general, and administrative (or SG&A) and research and development (or R&D) expenses to come in in the range of $1.5 billion and $1.55 billion for fiscal 2018. In Q2 2018, the company reported non-GAAP combined R&D and SG&A expenses close to $388 million.

Vertex Pharmaceuticals Is Expected to See Robust Revenue Growth
Posted on Thursday August 16, 2018

In its Q2 2018 earnings conference call, Vertex Pharmaceuticals (VRTX) updated its revenue guidance for fiscal 2018 from the previously projected range of $2.65 billion–$2.8 billion to $2.9 billion–$3.0 billion. The midpoint of this guidance range would imply a 36% year-over-year (or YoY) rise in revenues in fiscal 2018. This expectation has mainly been driven by the solid adoption of Symdeko since its launch in US markets. The company has not assumed the impact of securing new reimbursement for its CF drugs in markets outside the US in its fiscal 2018 revenue guidance.

United Therapeutics Announces Settlement Of Patent Litigation With Watson Laboratories, Inc. Relating To Tyvaso
Posted on Wednesday August 08, 2018

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , Aug. 8, 2018 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that it has entered into a Settlement Agreement with Watson ...

United Therapeutics Announces FREEDOM-EV Study Of Orenitram Meets Primary Endpoint
Posted on Wednesday August 08, 2018

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Aug. 8, 2018 /PRNewswire/ -- United Therapeutics Corporation (UTHR) today announced that preliminary analysis indicates that the FREEDOM-EV clinical study of Orenitram® (treprostinil) extended-release tablets in patients suffering from pulmonary arterial hypertension (PAH) has met its primary endpoint of delayed time to first clinical worsening event. Orenitram, when taken with an oral PAH background therapy, decreased the risk of a morbidity/mortality event versus placebo by 26% (p=0.0391). Efficacy was observed across the following key subgroups: age, gender, World Health Organization (WHO) functional class, PAH etiology and background PAH therapy.

Stock Market & Investing Books

Enter a stock symbol to view the stock details.